Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

mTOR inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	mTOR (149) 5-HT Receptor (3) Akt (21) Aminoacyl-tRNA Synthetase (1) AMPK (5) Amyloid-β (2) Antibiotic (6) Apoptosis (63) ASCT (1) ATM/ATR (7) ATP Synthase (2) Aurora Kinase (2) Autophagy (62) Bacterial (14) Bcl-2 Family (2) Bcr-Abl (1) c-Met/HGFR (1) Caspase (2) CDK (2) CRISPR/Cas9 (1) Cytochrome P450 (3) Deubiquitinase (1) DNA-PK (11) DNA/RNA Synthesis (2) Dopamine Receptor (3) Drug Metabolite (1) EGFR (5) Endogenous Metabolite (6) Epigenetic Reader Domain (1) ERK (1) FAK (1) FKBP (5) Fungal (5) Glutaminase (1) GSK-3 (1) HDAC (5) Hedgehog (2) HIF/HIF Prolyl-Hydroxylase (3) HSP (2) HSV (1) IGF-1R (1) IKK (5) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Isotope-Labeled Compounds (4) JNK (1) Keap1-Nrf2 (8) MALT1 (1) MDM-2/p53 (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) Mitophagy (5) Necroptosis (1) NF-κB (6) Nuclear Hormone Receptor 4A/NR4A (1) Parasite (1) PARP (1) PDGFR (2) PDK-1 (1) Phosphatase (1) PI3K (73) Pim (2) PINK1/Parkin (2) PKA (1) PKC (1) PPAR (1) Prolyl Endopeptidase (PREP) (2) Prostaglandin Receptor (1) Raf (2) Reactive Oxygen Species (4) RET (2) Ribosomal S6 Kinase (RSK) (2) ROR (1) Sirtuin (4) SphK (1) Src (4) STAT (3) TGF-beta/Smad (1) Topoisomerase (1) VEGFR (5) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (196) Cardiovascular Disease (6) Endocrinology (3) Infection (11) Inflammation/Immunology (21) Metabolic Disease (6) Neurological Disease (17)

By Targets:

mTOR (149)

5-HT Receptor (3)

Akt (21)

Aminoacyl-tRNA Synthetase (1)

AMPK (5)

Amyloid-β (2)

Antibiotic (6)

Apoptosis (63)

ASCT (1)

ATM/ATR (7)

ATP Synthase (2)

Aurora Kinase (2)

Autophagy (62)

Bacterial (14)

Bcl-2 Family (2)

Bcr-Abl (1)

c-Met/HGFR (1)

Caspase (2)

CDK (2)

CRISPR/Cas9 (1)

Cytochrome P450 (3)

Deubiquitinase (1)

DNA-PK (11)

DNA/RNA Synthesis (2)

Dopamine Receptor (3)

Drug Metabolite (1)

EGFR (5)

Endogenous Metabolite (6)

Epigenetic Reader Domain (1)

ERK (1)

FAK (1)

FKBP (5)

Fungal (5)

Glutaminase (1)

GSK-3 (1)

HDAC (5)

Hedgehog (2)

HIF/HIF Prolyl-Hydroxylase (3)

HSP (2)

HSV (1)

IGF-1R (1)

IKK (5)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Influenza Virus (1)

Isotope-Labeled Compounds (4)

JNK (1)

Keap1-Nrf2 (8)

MALT1 (1)

MDM-2/p53 (1)

Microtubule/Tubulin (2)

Mitochondrial Metabolism (1)

Mitophagy (5)

Necroptosis (1)

NF-κB (6)

Nuclear Hormone Receptor 4A/NR4A (1)

Parasite (1)

PARP (1)

PDGFR (2)

PDK-1 (1)

Phosphatase (1)

PI3K (73)

Pim (2)

PINK1/Parkin (2)

PKA (1)

PKC (1)

PPAR (1)

Prolyl Endopeptidase (PREP) (2)

Prostaglandin Receptor (1)

Raf (2)

Reactive Oxygen Species (4)

RET (2)

Ribosomal S6 Kinase (RSK) (2)

ROR (1)

Sirtuin (4)

SphK (1)

Src (4)

STAT (3)

TGF-beta/Smad (1)

Topoisomerase (1)

VEGFR (5)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (196)

Cardiovascular Disease (6)

Endocrinology (3)

Infection (11)

Inflammation/Immunology (21)

Metabolic Disease (6)

Neurological Disease (17)

218

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: mTOR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131344

mTOR inhibitor-8	mTOR Autophagy	Cancer
mTOR inhibitor-8 is an *mTOR* inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .

HY-118712

mTOR inhibitor WYE-23	mTOR	Cancer
mTOR inhibitor WYE-23 is a *mTOR* inhibitor, and IC₅₀ is 0.45 nM. It is selective to PI3Kα and IC₅₀ is 661 nM. mTOR inhibitor WYE-23 has antitumor activity .

HY-155376

mTOR inhibitor-14	mTOR	Cancer
mTOR inhibitor-14 (compound 14c) is a potent *mTOR* inhibitor. mTOR inhibitor-14 also shows minimal CYP2C8 inhibition. mTOR inhibitor-14 can inhibit tumor growth .

HY-160548

mTOR inhibitor-18	mTOR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
mTOR inhibitor-18 (Example 106) is a *mTOR* inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders .

HY-154958

mTOR inhibitor-12	mTOR	Neurological Disease
mTOR inhibitor-12 (Compound 11) is a selective brain penetrant *mTOR* inhibitor without genotoxicity risk. mTOR inhibitor-12 can be used for the research of CNS diseases .

HY-18353

mTOR inhibitor-3 3 Publications Verification	mTOR	Cancer
mTOR inhibitor-3 is a remarkably selective *mTOR* inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.

HY-154957

mTOR inhibitor-11	mTOR	Neurological Disease
mTOR inhibitor-11 (Compound 9) is a brain-penetrant *mTOR* inhibitor (IC₅₀: 21 nM for pS6). mTOR inhibitor-11 also inhibits pCHK1 and PDE4D with IC₅₀s of 17.2 and 17.0 μM. mTOR inhibitor-11 can be used for research of CNS disease .

HY-155211

mTOR inhibitor-13	mTOR PI3K	Cancer
mTOR inhibitor-13 (compound 9g), an aryl ureido compound, is a potent and selective *mTOR* inhibitor with an IC₅₀ of 0.29 nM. mTOR inhibitor-13 also inhibits PI3K-α with an IC₅₀ of 119 nM .

HY-111370

mTOR inhibitor-2	mTOR	Cancer
mTOR inhibitor-2 is a highlt potent, selective and oral *mTOR* inhibitor with an IC₅₀ of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates .

HY-112914

mTOR inhibitor-1 3 Publications Verification	mTOR Autophagy	Cancer
mTOR inhibitor-1 (Compound C-4) is an ATP-Competitive *mTOR* inhibitor which can suppress cells proliferation and inducing autophagy .

HY-118717

mTOR inhibitor WYE-28	mTOR	Cancer
mTOR inhibitor WYE-28 (compound 28) is a selective inhibitor of mTOR>/b< (IC₅₀)=0.08 nM. mTOR inhibitor WYE-28 inhibits PI3Kα with an IC50 value of 6 nM. mTOR inhibitor WYE-28 shows a metabolic time (T_1/2) in nude mouse microsomes of 13 min .

HY-114414

*HDACs/mTOR* Inhibitor 1** 1 Publications Verification	HDAC mTOR Apoptosis	Cancer
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC₅₀s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies .

HY-152238

*PI3K/mTOR* Inhibitor-12**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-12 is a potent, orally active and selective *PI3K/mTOR* inhibitor with IC₅₀ values of 0.06 nM and 3.12 nM for PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-12 has antitumor activity. PI3K/mTOR Inhibitor-12 has lower liver toxicity .

HY-147613

*PI3K/mTOR* Inhibitor-6**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent and dual inhibitor of *PI3K/mTOR*. PI3K/mTOR Inhibitor-6 displays better stability in artificial gastric fluids than gedatolisib. PI3K/mTOR Inhibitor-6 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-6 has the potential for the research of cancer diseases .

HY-151622

*PI3K/mTOR* Inhibitor-11**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-11 is an orally active *PI3K/mTOR* inhibitor (IC₅₀: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .

HY-141476

*PI3K/mTOR* Inhibitor-3**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-3 (compound 12), an imidazoline, is a potent PI3K and *mTOR* dual inhibitor. PI3K/mTOR Inhibitor-3 has anti-cancer activity .

HY-147614

*PI3K/mTOR* Inhibitor-7**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent and dual inhibitor of *PI3K/mTOR*. PI3K/mTOR Inhibitor-7 shows 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC₅₀ values). PI3K/mTOR Inhibitor-7 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-7 has the potential for the research of cancer diseases .

HY-146200

*PI3K/mTOR* Inhibitor-8**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-8 (Compound 18b) is a PI3K and *mTOR* dual inhibitor with IC₅₀ values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-8 induces HCT-116 cells apoptosis and arrests cell cycle at the G1/S phase .

HY-128333

*PI3K/mTOR* Inhibitor-4**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-4 is an orally active pan-class I *PI3K/mTOR* inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC₅₀ values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .

HY-156445

*PI3K/mTOR* Inhibitor-14**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-14 (compound Y-2) is a potent PI3K and *mTOR* dual inhibitor with IC₅₀s of 171.4 nM and 10.1 nM, respectively. PI3K/mTOR Inhibitor-14 has antitumor activities .

HY-153120A

*PI3K/mTOR* Inhibitor-13 sodium**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-153120

*PI3K/mTOR* Inhibitor-13**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-146016

PI3K/mTOR Inhibitor-5

PI3K mTOR Cancer

PI3K/mTOR Inhibitor-5 (compound 19a) is a potent and dual PI3K and mTOR inhibitor, with IC₅₀ values of 86.9 nM and 14.6 nM, respectively .

*PI3K/mTOR* Inhibitor-5**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-5 (compound 19a) is a potent and dual PI3K and *mTOR* inhibitor, with IC₅₀ values of 86.9 nM and 14.6 nM, respectively .

HY-147285

*PI3K/mTOR* Inhibitor-9**	mTOR PI3K	Neurological Disease
PI3K/mTOR Inhibitor-9 (Compound 1) is a potent *mTOR* and PI3K inhibitor with IC₅₀ values of 38 nM, 6.6 μM, 6.6 μM and 0.8 μM against mTOR (phospho-S6 cellular assay), PI3Kα, PI3Kγ and PI3Kδ, respectively .

HY-112602

*PI3K/mTOR* Inhibitor-1**	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual *PI3K/mTOR* inhibitor with IC₅₀s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and *mTOR*, respectively . Antitumor activity .

HY-111508

*PI3K/mTOR* Inhibitor-2** 1 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC₅₀s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for *mTOR* . Antitumor activity .

HY-101776

Desmethyl-VS-5584 Desmethyl-SB2343	mTOR PI3K	Cancer
Desmethyl-VS-5584 is a dimethyl analog of VS-5584 which is an potent and selective *mTOR/PI3K* dual inhibitor with pyrido [2,3-d] pyrimidine structure .

HY-118704

P-2281	mTOR	Inflammation/Immunology Cancer
P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P-2281 suppresses dextran sulfate sodium (DSS)-induced colitis by inhibiting T cell function and is efficacious in a murine model of human colitis .

HY-126077

MTI-31 LXI-15029	mTOR	Inflammation/Immunology Cancer
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for *mTOR* (K_d: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC₅₀ of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .

HY-109633

PI3K-IN-18	mTOR PI3K	Cancer
PI3K-IN-18 (Compound 1) is a PI3K inhibitor, and can also effectively inhibit the homologous enzymemTOR. The IC₅₀ values of PI3K-IN-18 for mTOR and PI3K-α were 49 nM and 41 nM, respectively .

HY-158039

YCH2823	Deubiquitinase Apoptosis	Cancer
YCH2823 is an inhibitor of USP7 (IC₅₀ = 49.6 nM; K_d = 0.117 μM). YCH2823 shows significant efficacy in inhibiting TP53 wild-type and mutant tumors, with approximately 5-fold higher potency than FT671. YCH2823 induce apoptosis. YCH2823 synergistic effects with mTOR inhibitors .

HY-N10754

Aschantin	mTOR Cytochrome P450	Infection Cardiovascular Disease Cancer
Aschantin, a bisepoxylignan, can be isolated from Magnolia biondii. Aschantin has antiplasmodial, Ca ²⁺-antagonistic, platelet activating factor-antagonistic, and chemopreventive activities. Aschantin is a *mTOR* kinase inhibitor. Aschantin is also an inhibitor of Cytochrome P450 and UGT enzyme .

HY-13328

Sapanisertib 25+ Cited Publications INK-128; MLN0128; TAK-228	mTOR Autophagy	Cancer
Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent *mTOR1/2* inhibitor with an IC₅₀ of 1 nM for mTOR kinase.

HY-141701

mTOR/HDAC-IN-1	mTOR HDAC	Cancer
mTOR/HDAC-IN-1 (Compound 50) is a selective *mTOR* and HDAC dual inhibitor with IC₅₀ values of 0.49 and 0.91 nM against mTOR and HDAC1, respectively. mTOR/HDAC-IN-1 can be studied as an anti-cancer agent .

HY-15272

WAY-600 5 Publications Verification	mTOR	Inflammation/Immunology Cancer
WAY-600 is a potent, ATP-competitive, and selective *mTOR* inhibitor with an IC₅₀ of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (mTORC1/2) assemble and activation.

HY-144449

mTOR/HDAC6-IN-1	mTOR HDAC Apoptosis Autophagy	Cancer
mTOR/HDAC6-IN-1 is a potent *mTOR* and HDAC6 dual inhibitor (IC₅₀s of 133.7 nM and 56 nM for mTOR and HDAC6, respectively). mTOR/HDAC6-IN-1 can induce significant autophagy, apoptosis and suppress migration. mTOR/HDAC6-IN-1 has potential to research Triple-negative breast cancer (TNBC) .

HY-151137

HSP90/mTOR-IN-1	mTOR HSP Apoptosis Autophagy	Cancer
HSP90/mTOR-IN-1 is a potent and orally active Hsp90 and *mTOR* inhibitor with IC₅₀ values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the *PI3K/AKT/mTOR* pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer .

HY-16956

Onatasertib 2 Publications Verification CC-223; ATG-008	mTOR Apoptosis	Cancer
Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of *mTOR* kinase, with an IC₅₀ value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.

HY-137996

Dehydrovomifoliol	Akt mTOR	Metabolic Disease
Dehydrovomifoliol is a *AKT/mTOR* dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .

HY-B0795

MHY1485 105+ Cited Publications	mTOR Autophagy	Cancer
MHY1485 is a potent cell-permeable *mTOR* activator that targets the ATP domain of mTOR. MHY1485 inhibits autophagy by suppression of fusion between autophagosomes and lysosomes .

HY-U00326

PI3Kα/mTOR-IN-1	PI3K mTOR	Cancer
PI3Kα/mTOR-IN-1 is a potent PI3Kα/mTOR dual inhibitor, with an IC₅₀ of 7 nM for PI3Kα in a cell assay, and K_is of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respectively.

HY-N0112

Dihydromyricetin 10+ Cited Publications Ampelopsin; Ampeloptin	mTOR Influenza Virus DNA/RNA Synthesis Autophagy	Infection Cancer
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-100398

PF-04979064 2 Publications Verification	PI3K mTOR	Cancer
PF-04979064 is a potent and selective *PI3K/mTOR* dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.

HY-U00434

3BDO

5+ Cited Publications

mTOR Autophagy Apoptosis Cancer

3BDO is a new mTOR activator which can also inhibit autophagy.

3BDO 5+ Cited Publications	mTOR Autophagy Apoptosis	Cancer
3BDO is a new *mTOR* activator which can also inhibit autophagy.

HY-111373

RapaLink-1 5 Publications Verification	mTOR Autophagy	Cancer
RapaLink-1, the third-generation bivalent *mTOR* inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .

HY-15269

PP30

mTOR PI3K Cancer

PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of mTOR with an IC₅₀ of 80 nM.
HY-124036

DS-7423

PI3K mTOR Cancer

DS-7423 is a dual PI3K and mTOR inhibitor, with IC₅₀ values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity .

PP30	mTOR PI3K	Cancer
PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of *mTOR* with an IC₅₀ of 80 nM.

HY-147913

PI3K/Akt/mTOR-IN-3	PI3K Akt mTOR Apoptosis	Cancer
PI3K/Akt/mTOR-IN-3 (compound 3d) is a potent *PI3K/AKT/mTOR* inhibitor. PI3K/Akt/mTOR-IN-3 displays the inhibitory activity in MCF-7, HeLa and HepG2 cells, with IC₅₀ values of 0.77, 1.23, and 4.57μM, respectively. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 and HeLa cells at the concentration of 4 μM. PI3K/Akt/mTOR-IN-3 induces cell apoptosis and S phase arrest .

HY-101963

AD80

Raf Src Ribosomal S6 Kinase (RSK) RET Cancer

AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.

HY-146751

PI3K/Akt/mTOR-IN-2 2 Publications Verification	PI3K Akt mTOR Apoptosis	Cancer
PI3K/Akt/mTOR-IN-2 is a *PI3K/AKT/mTOR* pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC₅₀ value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0112

Dihydromyricetin 10+ Cited Publications Ampelopsin; Ampeloptin	Infection Flavanonols Structural Classification Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	mTOR Influenza Virus DNA/RNA Synthesis Autophagy
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-N10754

Aschantin	Structural Classification Natural Products Source classification Magnoliaceae Yulania biondii (Pamp.) D. L. Fu Plants	mTOR Cytochrome P450
Aschantin, a bisepoxylignan, can be isolated from Magnolia biondii. Aschantin has antiplasmodial, Ca ²⁺-antagonistic, platelet activating factor-antagonistic, and chemopreventive activities. Aschantin is a *mTOR* kinase inhibitor. Aschantin is also an inhibitor of Cytochrome P450 and UGT enzyme .

HY-137996

Dehydrovomifoliol	Artemisia frigida Willd. Structural Classification Terpenoids Sesquiterpenes Source classification Plants Compositae	Akt mTOR
Dehydrovomifoliol is a *AKT/mTOR* dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .

HY-119767

Jolkinolide A	Structural Classification Euphorbia fischeriana Steud. Terpenoids Source classification Diterpenoids Euphorbiaceae Plants	VEGFR Apoptosis
Jolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the *Akt-STAT3-mTOR* signaling pathway and reduces the expression of VEGF in A549 cells .

HY-N4315

Pomiferin NSC 5113	Classification of Application Fields Source classification Phenols Polyphenols Maclura pomifera (Raf.) Schneid. Plants Moraceae Disease Research Fields Cancer	HDAC mTOR
Pomiferin (NSC 5113) acts as an potential inhibitor of HDAC, with an IC₅₀ of 1.05 μM, and also potently inhibits *mTOR* (IC₅₀, 6.2 µM).

HY-N1244

Sarmentosin Sarmentosine; Sarmentosine (glycoside)	Structural Classification Natural Products Animals Source classification Saccharides Monosaccharides	Keap1-Nrf2 mTOR Apoptosis
Sarmentosin is an activator of Nrf2. Sarmentosin inhibits *mTOR* signaling and induces autophagy-dependent apoptosis in human HCC cells .

HY-N0656A

(+)-Usnic acid 2 Publications Verification	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids lichen Plants Disease Research Fields Cancer	mTOR Bacterial Autophagy
(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of *mTOR, and inhibits* mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity . (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium .

HY-127067

Yuanhuadin	Structural Classification Terpenoids Thymelaeaceae Source classification Diterpenoids Plants Daphne genkwa Sieb. et Zucc.	Akt EGFR mTOR
Yuanhuadin, extracted from Genkwa Flos Daphne genkwa, has antitumor activity through inhibiting *Akt/mTOR* and EGFR pathways, induce cell-cycle arrest and abortion .

HY-13595

Chrysophanol 3 Publications Verification Chrysophanic acid	Quinones Structural Classification Classification of Application Fields Rheum palmatum L. Anthraquinones Polygonaceae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR
Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and *mTOR/p70S6K*.

HY-10219

Rapamycin Maximum Cited Publications 728 Publications Verification Sirolimus; AY-22989	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Source classification Disease Research Endogenous metabolite Disease Research Fields Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-N2051

Zeylenone	Natural Products Classification of Application Fields Uvaria grandiflora Roxb. Source classification Plants Annonaceae Disease Research Fields Cancer	Apoptosis
Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways .

HY-N1338

Royleanone NSC 122417	Quinones Structural Classification Anthraquinones Labiatae Source classification Plants Vachellia nilotica (L.) P. J. H. Hurter & Mabb.	mTOR Akt
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits *mTOR/PI3/AKT* signaling pathway in LNCaP prostate cancer cells .

HY-N0109

Salidroside 15+ Cited Publications Rhodioloside	Structural Classification Classification of Application Fields Rhodiola rosea Linn. Crassulaceae Source classification Phenols Plants Disease Research Fields Cancer	PINK1/Parkin mTOR Apoptosis Prolyl Endopeptidase (PREP)
Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating *mTOR* signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.

HY-N1333

Rubioncolin C	Quinones Monophenols Classification of Application Fields Rubia podantha Source classification Rubiaceae Phenols Plants Naphthalene Quinones Disease Research Fields Cancer	NF-κB
Rubioncolin C exerts anti-tumor activity by inducing apoptotic and autophagic Cell Death and inhibiting the NF-κB and *Akt/mTOR/P70S6K* Pathway in Human Cancer Cells .

HY-N0072

Brazilin	Structural Classification Natural Products Classification of Application Fields Leguminosae Caesalpinia sappan L. Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	Apoptosis Autophagy
Brazilin is a red dye precursor obtained from the heartwood of several species of tropical hardwoods. Brazilin inhibits the cells proliferation, promotes apoptosis, and induces autophagy through the AMPK/mTOR pathway. Brazilin shows chondroprotective and anti-inflammatory activities .

HY-13595R

Chrysophanol (Standard) Chrysophanic acid (Standard)	Quinones Structural Classification Classification of Application Fields Rheum palmatum L. Polygonaceae Source classification Phenols Plants Disease Research Fields Cancer	EGFR
Chrysophanol (Standard) is the analytical standard of Chrysophanol. This product is intended for research and analytical applications. Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and *mTOR/p70S6K*.

HY-N3354

Lupiwighteone 8-prenylgenistein	Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields Isoflavones Cancer	Apoptosis
Lupiwighteone is an isoflavone present widely in wild-growing plants, with antioxidant, antimicrobial and anticancer effects. Lupiwighteone induces caspase-dependent and -independent apoptosis on human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway .

HY-N0712

Typhaneoside 1 Publications Verification	Cardiovascular Disease Flavonols Flavonoids Classification of Application Fields Typhaceae Source classification Typha angustifolia L. Phenols Polyphenols Plants Disease Research Fields	Autophagy
Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function .

HY-N0279

Cardamonin 5+ Cited Publications Cardamomin; Alpinetin chalcone	Structural Classification Chalcones Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Boesenbergia rotunda Plants Disease Research Fields Cancer Zingiberaceae	NF-κB STAT Wnt β-catenin Bcl-2 Family Apoptosis
Cardamonin can be found from cardamom, and target various signaling molecules, transcriptional factors, cytokines and enzymes. Cardamonin can inhibit *mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin* and COX-2. Cardamonin shows anticancer, anti-inflammatory, antimicrobial and antidiabetic activities .

HY-N6843

Arnicolide D 1 Publications Verification	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Euchresta horsfieldii (Lesch.) J. Benn. Plants Compositae Disease Research Fields Cancer	Caspase PI3K Akt mTOR STAT
Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the caspase signaling pathway and inhibits the *PI3K/AKT/mTOR* and STAT3 signaling pathways. Arnicolide D inhibits Nasopharyngeal carcinoma (NPC) cell viability in a concentration- and time-dependent manner .

HY-N0047

Polyphyllin I 1 Publications Verification	Structural Classification Liliaceae Classification of Application Fields Paris polyphylla Smith Plants Disease Research Fields Saccharides Steroids Cancer	JNK mTOR Akt PDK-1 Autophagy Apoptosis
Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the JNK signaling pathway and is an inhibitor of *PDK1/Akt/mTOR* signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis .

HY-N0109R

Salidroside (Standard) Rhodioloside (Standard)	Structural Classification Classification of Application Fields Rhodiola rosea Linn. Crassulaceae Source classification Phenols Plants Disease Research Fields Cancer	Prolyl Endopeptidase (PREP) mTOR Apoptosis PINK1/Parkin
Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating *mTOR* signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy .

HY-N6896

Isoviolanthin	Flavonoids other families Classification of Application Fields Flavones Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	TGF-beta/Smad
Isoviolanthin, a flavonoid glycoside, could markedly inhibit TGF-β1-mediated migration and invasion by deactivating epithelial-mesenchymal transition (EMT) via the TGF-β/Smad and *PI3K/Akt/mTOR* pathways in HCC cells. Isoviolanthin exhibits no cytotoxic effects on normal liver LO2 cells .

HY-125927

8-Aminoadenosine 8-NH2-Ado	Structural Classification Natural Products Source classification Endogenous metabolite	DNA/RNA Synthesis Akt mTOR Autophagy Apoptosis
8-Aminoadenosine (8-NH2-Ado), a RNA-directed nucleoside analogue, reduces cellular ATP levels and inhibits mRNA synthesis. 8-Aminoadenosine blocks *Akt/mTOR* signaling and induces autophagy and apoptosis in a p53-independent manner. 8-Aminoadenosine has antitumor activity .

HY-N0107

Cyclovirobuxine D	Cardiovascular Disease Structural Classification Alkaloids Classification of Application Fields Buxaceae Plants Disease Research Fields Buxus microphylla S.et Z.var. Sinica Rehd.et Wils.	Apoptosis Autophagy mTOR Akt
Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and *mTOR* . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .

HY-124896

Bonannione A 6-Geranylnaringenin; Mimulone	Paulownia tomentosa (Thunb.) Steud. Scrophulariaceae Plants	Phosphatase Apoptosis Autophagy
Bonannione A (6-Geranylnaringenin; Mimulone), a prenylflavonoid, is an orally active and potent protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 14 µM. Bonannione A triggers caspase-dependent apoptosis. Bonannione A induces autophagy through p53-mediated AMPK/mTOR pathway. Bonannione A shows anti-inflammatory, antiradical and anti-cancer activity .

HY-B1232

Metyrapone 5 Publications Verification Su-4885	Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Cancer	Endogenous Metabolite Cytochrome P450 Autophagy
Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression .

HY-113038

D-α-Hydroxyglutaric acid (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Classification of Application Fields Neurological Disease Anti-aging Source classification Endocrine diseases Endogenous metabolite Immune System Disorder Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Disease Research Fields Inflammation/Immunology Cancer	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits *mTOR* signaling .

HY-100542

D-α-Hydroxyglutaric acid disodium 2 Publications Verification Disodium (R)-2-hydroxyglutarate	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits *mTOR* signaling .

HY-B1232A

Metyrapone Tartrate Su-4885 Tartrate	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Cytochrome P450 Autophagy mTOR
Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of *mTOR* pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression .

HY-N0787

Cryptochlorogenic acid 1 Publications Verification 4-Caffeoylquinic acid; 4-O-Caffeoylquinic acid	Structural Classification Classification of Application Fields Source classification Plants Moraceae Endogenous metabolite Simple Phenylpropanols Other Diseases Phenols Polyphenols Phenylpropanoids Disease Research Fields Morus alba Linn.	Endogenous Metabolite NF-κB Keap1-Nrf2 mTOR HIF/HIF Prolyl-Hydroxylase
Cryptochlorogenic acid (4-Caffeoylquinic acid) is a naturally occurring phenolic acid compound with oral effectiveness, anti-inflammatory, antioxidant and anti-cardiac hypertrophy effects. Alleviating LPS (HY-D1056) and ISO (HY-B0468) by regulating proinflammatory factor expression, inhibiting NF-κB activity, promoting Nrf2 nuclear transfer, and regulating PI3Kα/Akt/ *mTOR* / HIF-1α signaling pathway Induced physiological stress response .

HY-N8380

(-)-Latifolin	Structural Classification Dalbergia hupeana Hance Source classification Phenols Polyphenols Plants Fabaceae	Apoptosis Autophagy PI3K Necroptosis
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting *PI3K/AKT/mTOR/p70S6K* signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-16561

Resveratrol 75+ Cited Publications trans-Resveratrol; SRT501	Structural Classification Classification of Application Fields Anti-aging Source classification Vitis vinifera cv. Zalema Plants Vitaceae Infection Microorganisms Functional Molecules Sunscreen Research of Health Products Phenols Polyphenols Cosmetic Research Inflammation/Immunology Disease Research Fields Cancer	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including *mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-N0281

Daphnetin 2 Publications Verification 7,8-Dihydroxycoumarin	Classification of Application Fields Daphne Thymelaeaceae Source classification Coumarins Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Cancer	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species Caspase Bcl-2 Family PARP Parasite
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1ß, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-16561R

Resveratrol (Standard) 75+ Cited Publications trans-Resveratrol (Standard); SRT501 (Standard)	Infection Functional Molecules Classification of Application Fields Sunscreen Anti-aging Source classification Research of Health Products Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (Standard) is the analytical standard of Resveratrol. This product is intended for research and analytical applications. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including *mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

Cat. No.	Product Name	Chemical Structure

HY-10219S

Rapamycin-d3
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

HY-B0965AS

Thioridazine-d3 hydrochloride

Thioridazine-d₃ (hydrochloride) is the deuterium labeled Thioridazine. Thioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs)[1][2][3][4].

HY-10218S

Everolimus-d4
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].

HY-137315S

TML-6-d3
TML-6-d₃ is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-

HY-10219S1

Rapamycin-13C,d3

Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-16561S1

Resveratrol-13C6

Resveratrol- ¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-16561S

Resveratrol-d4

Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks